Express Scripts valuation already reflects Q1 miss, says Jefferies Jefferies believes the valuation of Express Scripts shares "more than adequately" reflects the company's miss in Q1. The firm finds the stock attractive and maintains a Buy rating on the name with an $86 price target.
Express Scripts CEO says Gilead relationship 'important' going forward Express Scripts (ESRX) CEO George Paz at the J.P. Morgan Healthcare Conference said his company's relationship with Gilead (GILD) is "important" going forward. Paz said his company's goal is not to exclude drugs. He continues to discuss Express Scripts's deal with AbbVie (ABBV) and the company's goal of saving clients money with regards to healthcare costs.